bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

Autor: NM Walter, Max Robinson, R. G. Charlton, David E. Neal, JA Royds, Freddie C. Hamdy, I. Apakama, CE Fuller

Publikováno v: British Journal of Cancer

Seventy-seven men with histologically proven and newly diagnosed prostate cancer we investigated for the presence of bcl-2 protein overexpression and p53 protein accumulation 1 immunohistochemistry. Forty-five men had evidence of locally advanced and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ce67da5291c3c424490ffb46ca18024
https://doi.org/10.1038/bjc.1996.526

Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival.

Autor: Burgess ER; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand., Crake RLI; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.; Metastasis Research Laboratory, GIGA-Cancer, University of Liège, Liege, Belgium., Phillips E; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand., Morrin HR; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.; Cancer Society Tissue Bank, University of Otago Christchurch, Christchurch, New Zealand., Royds JA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Slatter TL; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Wiggins GAR; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand., Vissers MCM; Centre for Free Radical Research, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand., Robinson BA; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.; Canterbury Regional Cancer and Haematology Service, Canterbury District Health Board, and Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand., Dachs GU; Mackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago Christchurch, Christchurch, New Zealand.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Mar 28; Vol. 12, pp. 829524. Date of Electronic Publication: 2022 Mar 28 (Print Publication: 2022).

Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk.

Autor: Eiholzer RA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Mehta S; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand., Kazantseva M; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand., Drummond CJ; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand., McKinney C; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Young K; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Slater D; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.; Hunter Medical Research Institute, New South Wales 2305, Australia., Morten BC; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.; Hunter Medical Research Institute, New South Wales 2305, Australia., Avery-Kiejda KA; Priority Research Centre for Cancer Research, Innovation and Translation and the Hunter Cancer Research Alliance, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales 2305, Australia.; Hunter Medical Research Institute, New South Wales 2305, Australia., Lasham A; Department of Molecular Medicine and Pathology, University of Auckland, Auckland 1023, New Zealand., Fleming N; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Morrin HR; Department of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand., Reader K; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Royds JA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Landmann M; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand., Petrich S; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand., Reddel R; Children's Medical Research Institute, University of Sydney, Westmead, New South Wales 2145, Australia., Huschtscha L; Children's Medical Research Institute, University of Sydney, Westmead, New South Wales 2145, Australia., Taha A; Department of Neurosurgery, Southern District Heath Board, Dunedin 9016, New Zealand., Hung NA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand., Slatter TL; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand., Braithwaite AW; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, Dunedin 9016, New Zealand.; Malaghan Institute of Medical Research, Wellington 6242, New Zealand.

Publikováno v: Cancers [Cancers (Basel)] 2020 Sep 01; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 01.

Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.

Autor: Kazantseva M; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, New Zealand., Eiholzer RA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Mehta S; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, New Zealand., Taha A; Department of Neurosurgery, Southern District Heath Board, New Zealand., Bowie S; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Roth I; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Zhou J; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.; Department of Radiology, Southern District Health Board, New Zealand., Joruiz SM; Jacqui Wood Cancer Centre, Division of Cancer Research, University of Dundee, UK., Royds JA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Hung NA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Slatter TL; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Braithwaite AW; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.; Maurice Wilkins Centre for Molecular Biodiscovery, New Zealand.

Publikováno v: The Journal of pathology [J Pathol] 2018 Sep; Vol. 246 (1), pp. 77-88. Date of Electronic Publication: 2018 Jul 31.

Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.

Autor: Hung NA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Eiholzer RA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Kirs S; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Zhou J; Department of Radiology, Southern District Health Board, Dunedin, New Zealand., Ward-Hartstonge K; Department of Microbiology and Immunology, Dunedin School of Medical Sciences, University of Otago, Dunedin, New Zealand., Wiles AK; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Frampton CM; Department of Medicine, University of Otago, Christchurch, New Zealand., Taha A; Neurosurgery, Southern District Health Board, Dunedin, New Zealand., Royds JA; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Slatter TL; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2016 Mar; Vol. 29 (3), pp. 212-26. Date of Electronic Publication: 2016 Jan 15.